ArticleCNS neuroscience & therapeutics2026
Disodium Cromoglycate Attenuates the Depressive-Like Behaviors in Mice by Inhibiting Neuroinflammation.
Article in CNS neuroscience & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Disodium Cromoglycate Attenuates the Depressive-Like Behaviors in Mice by Inhibiting Neuroinflammation.CNS neuroscience & therapeutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
aimsEmerging evidence indicates that mast cells (MCs) may play a crucial role in the pathogenesis of major depression disorder (MDD). This study aimed to investigate whether the mast cell membrane stabilizer Disodium cromoglycate (DSCG) could ameliorate depressive-like behaviors by attenuating mast cell-mediated neuroinflammation.
methodsLipopolysaccharide (LPS)-induced and chronic restraint stress (CRS)-induced mouse models were induced in C57BL/6 mice to evaluate the therapeutic effect of the DSCG. Depressive-like behaviors were assessed using the sucrose preference test (SPT), tail suspension test (TST), and forced swimming test (FST). Histopathological and molecular changes were examined through immunofluorescence, western blot, RT-qPCR, and ELISA.
resultsFirstly, our results indicated that the number of MCs was increased in the brain from LPS-induced depression model mice. Secondly, both CRS and LPS-induced depressive-like behaviors were significantly ameliorated by DSCG. Moreover, treatment with DSCG could down-regulate the expression of MCs-associated genes in the brain of depression model mice. Mechanically, our results displayed that the use of DSCG significantly suppressed the activation of glial cells and the expression of pro-inflammatory factors.
conclusionOur study demonstrates that MCs infiltration and activation contribute to neuroinflammation in LPS-induced depressive mice. DSCG exerts its antidepressant effects primarily by modulating MCs-mediated neuroinflammation. These results highlight DSCG as a promising therapeutic candidate for the treatment of inflammation-associated depression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.